Shilpa CDMO投资5000万美元扩大印度Raichur多肽产能,首条商业化产线2026年12月投产
Shilpa CDMO Commits $50 Million to Scale Peptide Capacity in India
Shilpa CDMO于2026年11月3日宣布投资5000万美元,在印度卡纳塔克邦Raichur的Unit-I园区扩建多肽生产,将分阶段新增10 kL固相多肽合成(SPPS)反应器产能。首条商业化产线计划2026年12月投产,配备500-L和1000-L反应器,年产能最高1吨,全部建成后共6条并行cGMP产线。
Shilpa CDMO's $50 million plan adds 10 kL of SPPS reactor capacity in Raichur, India, with its first commercial peptide line opening in December 2026.
Shilpa CDMO announced on November 3, 2026, that it is investing $50 million to expand peptide manufacturing at its Unit-I campus in Raichur, Karnataka, India, citing accelerating demand for glucagon-like peptide-1s (GLP-1s) and more complex peptide therapeutics.¹ The phased investment will add 10 kL of solid-phase peptide synthesis (SPPS) reactor capacity over the next few years. It begins with a commercial manufacturing line scheduled to open in December 2026.¹
Key facts
- Company: Shilpa CDMO (Shilpa Pharma Lifesciences)
- Investment: $50 million, phased over the next few years
- Site: Unit-I campus, Raichur, Karnataka, India
- Added capacity: 10 kL of SPPS reactor capacity
- First commercial line: opens December 2026 (500-L and 1000-L reactors)
- Line output: up to 1 metric ton per year
- Total lines: 6 parallel cGMP lines when complete
- Synthesis routes: SPPS, LPPS, and hybrid
- Focus: GLP-1s and complex peptides, including conjugates and radioligand peptides
"Peptides are becoming one of the most important areas of pharmaceutical development, but the opportunity goes well beyond current GLP-1 demand,” said Keshav Bhutada, CEO of Shilpa CDMO, in a company press release.¹ “Innovator pipelines in oncology and rare diseases are producing increasingly sophisticated molecules and conjugates that require much greater expertise in route design, synthesis, purification and scale-up."
What capacity is Shilpa CDMO adding?
The new commercial line will join 3 existing clinical-phase manufacturing lines at the Raichur Unit-I campus, with commercial supply ramping up through 2027.¹ It features 500-L and 1000-L reactors in a single block, supporting annual production of up to 1 metric ton.¹ Purification includes a pair of 2-m dynamic axial compression (DAC) columns with a 10,000-L/h preparative high-performance liquid chromatography system. The line also has 1000-L/h nanofiltration and a 1000-L lyophilizer.¹
The company plans to add further 2-kL, 3-kL, and 5-kL SPPS reactors, which it said will establish one of the largest multi-ton peptide capacities in India.¹ The expanded operation will comprise 6 parallel current good manufacturing practice lines, allowing multiple programs to run independently. One of those lines is dedicated to cytotoxic peptide manufacturing using SPPS.¹
The facility will use a centralized distributed control system with integrated process analytical technology and UV monitoring. Design of experiments and process simulation will be used to set operating parameters ahead of scale-up and technology transfer.¹
Which peptide chemistries will the platform support?
The platform supports SPPS, liquid-phase peptide synthesis (LPPS), and hybrid SPPS plus LPPS routes, as well as linear, cyclic, and branched peptides. Capabilities include unnatural and D-amino acids, lipidation, conjugation, and radioligand peptides.¹ More than 100 scientists and manufacturing specialists work in the peptide business, including an R&D team of more than 50 dedicated to peptide chemistries.¹
"For longer peptides, that can mean moving from solid-phase synthesis to a hybrid fragment-based route as volumes grow," said Dipak Kalita, senior vice president of CDMO services at Shilpa CDMO, in the release.¹
The investment follows the launch of Shilpa CDMO as a dedicated complex-molecule brand of Shilpa Pharma Lifesciences at CPHI Milan in October 2026. At the time, the company said it would announce details of commercial-scale peptide manufacturing there.²
How does it fit the broader peptide manufacturing landscape?
Other CDMOs have also moved to expand peptide capabilities. On November 2, 2026, Samsung Biologics reported that 97.66% of PolyPeptide Group's shares had been tendered in its offer for the peptide API CDMO.³ PolyPeptide describes itself as serving a fast-growing market with significant exposure to metabolic diseases, including GLP-1.³ In 2025, SK pharmteco announced a $6.1 million investment in kilo-scale SPPS and purification operations in Rancho Cordova, California. The company said the investment would help overcome purification bottlenecks in peptide scale-up.⁴
What are the limitations?
Most of the planned reactor capacity will be phased in over the next few years, and the company did not specify timelines for each reactor addition. Shilpa CDMO did not name customers, programs, or committed volumes for the new capacity. Its description of one of India's largest peptide capacities is the company's own characterization.
References
- Shilpa CDMO. Shilpa CDMO to invest $50 million in commercial peptide manufacturing. Press release. Published November 3, 2026. Received via email November 3, 2026.
- Shilpa CDMO. Complex-molecule specialist Shilpa CDMO launches at CPHI Milan. Press release. Published September 9, 2026. Accessed November 3, 2026.
- Samsung Biologics. Samsung Biologics publishes provisional end result for PolyPeptide tender offer with 97.99% participation rate. Press release. Published November 2, 2026. Accessed November 3, 2026. https://samsungbiologics.com/media/company-news/samsung-biologics-publishes-provisional-end-result-for-polypeptide-tender-offer-with-97dot99
- SK pharmteco. SK pharmteco boosts domestic peptide scale-up with investment in California facility. Press release. Published October 23, 2025. Accessed November 3, 2026. https://www.skpharmteco.com/news-insights/press-release/sk-pharmteco-boosts-domestic-peptide-scale-up-with-investment-in-california-facility/
Related to this article
October 30th, 2026
Lonza's Visp expansion adds 3 multiproduct suites at up to 1200 L plus 500-L single-use capacity to scale commercial ADC production from 2028.
November 3rd, 2026
Final FDA guidance replaces 2011 potency testing advice, asking CGT makers to build potency assurance from IND filing through postmarket monitoring.
November 2nd, 2026
Samsung Biologics' pending PolyPeptide deal adds peptide API manufacturing, including GLP-1 supply, to its antibody and ADC CDMO services.
October 30th, 2026
Industry experts discuss how reshoring, fill/finish capacity, and cold chain technology are shaping a more resilient biopharma supply chain.
October 28th, 2026
All 9 patients treated with BB-301 gene therapy met formal response criteria for improved swallowing in an ongoing OPMD trial.
November 3rd, 2026
Teva will commercialize etanercept-ykro (Eticovo) and infliximab-abda, adding 2 TNF inhibitor biosimilars to US options for inflammatory diseases.
November 2nd, 2026
CAR-T transformed blood cancer care, but solid and brain tumors demand different delivery, manufacturing, and safety strategies to work.
November 2nd, 2026
Inovio reports that Voceryq spared 27% of adults with recurrent respiratory papillomatosis from surgery for 12 months in a 26-patient efficacy group.
来源:BioPharm International · biopharminternational.com







